GR 144053 trihydrochloride
Cat. No. 1263
Chemical Name: 4-[4-[4-(Aminoiminomethyl)phenyl]-1
Biological ActivityA potent and selective platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist (IC50 = 37 nM). Orally active and highly effective at inhibiting thrombus formation in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Matsuno et al (1999) Comparative antiplatelet effects of aspirin, vapiprost and GR 144053, a GPIIb/IIIa antagonist with special reference to the role of platelet microaggregates. Br.J.Pharmacol. 127 1129. PMID: 10455258.
Matsuno et al (1997) GR 144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br.J.Pharmacol. 122 1099. PMID: 9480031.
Eldred et al (1994) Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad spectrum antithrombotic agent. J.Med.Chem. 37 3882. PMID: 7966149.
If you know of a relevant reference for GR 144053 trihydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GR 144053 trihydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GR 144053 trihydrochloride, supplier, Glycoprotein, IIb/IIIa, αIIbβ3, alphaIIbβ3, beta3, antagonists, Antithrombotic, receptor, Adhesion, Molecules, Integrin, Receptors, GR144053, trihydrochloride, Tocris Bioscience, Integrin Inhibitor products
Find multiple products by catalog number
New Products in this Area
DR5 (TRAIL receptor) agonist; induces apoptosisBOP
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCsATN 161
α5β1 integrin receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.